Genitourinary Cancers

February 12, 2021 - Tivozanib led to a significantly greater quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy versus sorafenib in patients with metastatic renal cell carcinoma.

February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.

February 12, 2021 - Atezolizumab monotherapy showed favorable outcomes compared with chemotherapy alone as frontline treatment for patients with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma.

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib

February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

February 11, 2021 - Avelumab as frontline maintenance therapy plus best supportive care showed a favorable benefit-risk balance in Japanese patients with advanced urothelial cancer that did not progress on first-line chemotherapy.

February 11, 2021 - First-line treatment with immune checkpoint inhibitor–based regimens could be linked with an improvement in overall survival versus select targeted therapies in patients with metastatic non–clear cell renal cell carcinoma.

February 11, 2021 - Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma regardless of mTOR or PTEN status.

February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.

February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

Health care experts remark on current unmet needs associated with the use of novel therapies, such as immunotherapies, and targeted treatments for metastatic renal cell carcinoma and share advice on best practices when managing patients in the community.

Robert Alter, MD, highlights various trial data on the management of advanced renal cell carcinoma with the combination of lenvatinib and everolimus, also commenting on the potential outcomes associated with the use of lenvatinib with pembrolizumab.

During the question-and-answer portion of the virtual Institutional Perspectives in Cancer webinar, Earle Burgess, MD, and colleagues provide insight into how they are navigating the evolving treatment landscape of renal cell carcinoma and bladder cancer.

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

In our exclusive interview, Toni K. Choueiri, MD, provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell carcinoma.

January 25, 2021 - The European Commission has approved avelumab for use as a frontline maintenance option in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

January 22, 2021 - The FDA has approved the combination of nivolumab plus cabozantinib for the frontline treatment of patients with advanced renal cell carcinoma.

Robert Motzer, MD, describes what lenvatinib is and explains the rationale for studying its use in combination with novel therapies such as everolimus as treatment for metastatic renal cell carcinoma.

Oncologists discuss their preferences in regard to second-line therapy for metastatic renal cell carcinoma, and optimal timing for changing regimens based on responses to treatment.

January 21, 2021 - The FDA has granted priority review to a biologics license application for retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who were intolerant of or who had progressed on platinum-based chemotherapy.